CLOs on the Move

CorMedix

www.cormedix.com

 
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, ...
  • Number of Employees: 100-250
  • Annual Revenue: $250-500 Million
  • www.cormedix.com
  • 400 Connell Drive Suite 5000
    Bridgewater, NJ USA 08807
  • Phone: 908.517.9500

Executives

Name Title Contact Details
Beth Zelnick Kaufman
 EVP, Chief Legal Officer and Profile
Zelnick Kaufman
 Chief Legal Officer Profile
Beth Kaufman
 Executive Vice President, Chief Legal Officer, and Corporate Secretary Profile
Phoebe Mounts
 Executive Vice President and General Counsel Profile
Phoebe Mounts
 Executive Vice President and General Counsel Profile

Similar Companies

Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme`s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company`s partners make progress developing and commercializing their products being developed using ENHANZE®

Provident Clinical Research and Consulting

Provident Clinical Research & Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioWa

BioWa is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Primorigen Biosciences

Primorigen Biosciences LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Qiagen

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).